These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

582 related items for PubMed ID: 16151039

  • 1. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.
    Gomberg-Maitland M, Tapson VF, Benza RL, McLaughlin VV, Krichman A, Widlitz AC, Barst RJ.
    Am J Respir Crit Care Med; 2005 Dec 15; 172(12):1586-9. PubMed ID: 16151039
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension.
    Sitbon O, Manes A, Jais X, Pallazini M, Humbert M, Presotto L, Paillette Ld, Zaccardelli D, Davis G, Jeffs R, Simonneau G, Galie N.
    J Cardiovasc Pharmacol; 2007 Jan 15; 49(1):1-5. PubMed ID: 17261956
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial.
    Hiremath J, Thanikachalam S, Parikh K, Shanmugasundaram S, Bangera S, Shapiro L, Pott GB, Vnencak-Jones CL, Arneson C, Wade M, White RJ, TRUST Study Group.
    J Heart Lung Transplant; 2010 Feb 15; 29(2):137-49. PubMed ID: 20022264
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension.
    Lang I, Gomez-Sanchez M, Kneussl M, Naeije R, Escribano P, Skoro-Sajer N, Vachiery JL.
    Chest; 2006 Jun 15; 129(6):1636-43. PubMed ID: 16778286
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
    Keogh AM, Jabbour A, Weintraub R, Brown K, Hayward CS, Macdonald PS.
    J Heart Lung Transplant; 2007 Nov 15; 26(11):1079-83. PubMed ID: 18022071
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials.
    Benza RL, Gomberg-Maitland M, Naeije R, Arneson CP, Lang IM.
    J Heart Lung Transplant; 2011 Sep 15; 30(9):982-9. PubMed ID: 21531577
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.